01—Abstract
Summary
Summary of the 10-Q filed July 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported second-quarter 2025 total revenues of $568.3 milliona, down from $637.2 million in the second quarter of 2024, while net product revenues rose to $520.0 million from $437.6 million.
Net income for the quarter was $184.8 millionb, or $0.65 per share on a diluted basis, compared with $226.1 million, or $0.77 per share diluted, a year earlier. For the six months ended June 30, 2025, total revenues were $1.12 billion and net income was $344.5 million. Growth in CABOMETYX net product revenues was driven by continued demand for the nivolumab combination in first-line advanced renal cell carcinoma, and the company projects net product revenues may increase for the remainder of 2025 following the first-quarter 2025 FDA approval for previously treated advanced neuroendocrine tumors.
Collaboration revenues fell to $48.2 millionc in the quarter from $199.6 million, reflecting the $150.0 million Ipsen commercial milestone recognized in the prior-year period. Cash, cash equivalents and marketable securities totaled $1.39 billion at June 30, 2025, down from $1.75 billion at December 31, 2024, primarily due to share repurchases. The company repurchased $796.3 million of common stock under two $500.0 million authorizations, leaving approximately $203.7 million available through December 31, 2025.
Management states that current cash and marketable securities, together with net product and collaboration revenues, will enable it to maintain operations for at least 12 months. Research and development expenses were $200.4 milliond in the quarter, and the company expects clinical trial costs to increase for the remainder of 2025, driven mainly by zanzalintinib studies. The filing also discusses significant patent litigation over CABOMETYX generics.
In July 2025, Exelixis entered into a settlement and license agreement with Biocon that grants a U.S. generic license beginning January 1, 2031, subject to FDA approval. Litigation with MSN, Sun and Azurity remains ongoing, and the company states it is not possible at this time to determine the likelihood of an unfavorable outcome. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib in June 2025 and intends to discuss a New Drug Application filing with U.S. regulators.
02—Key points
Key Highlights
- Total revenues were $568.3 million in Q2 2025, versus $637.2 million in Q2 2024, while net product revenues increased to $520.0 million from $437.6 million.
- Net income was $184.8 million ($0.65 diluted EPS) in Q2 2025, compared with $226.1 million ($0.77 diluted EPS) in Q2 2024.
- Collaboration revenues declined to $48.2 million from $199.6 million, reflecting the $150.0 million Ipsen commercial milestone recognized in Q2 2024.
- Cash, cash equivalents and marketable securities were $1.39 billion at June 30, 2025, down from $1.75 billion at December 31, 2024.
- Repurchased $796.3 million of common stock under two $500.0 million authorizations; approximately $203.7 million remains available before December 31, 2025.
- Settled CABOMETYX patent litigation with Biocon in July 2025, granting a U.S. generic license beginning January 1, 2031, if approved by the FDA; MSN, Sun and Azurity litigation remains pending.
- Announced positive top-line STELLAR-303 phase 3 results for zanzalintinib versus regorafenib in June 2025 and intends to discuss a U.S. New Drug Application with regulators.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2026, Exelixis kept $0.33.
- Revenue$568.3M100.0%
- Cost of revenue−$19.5M3.4%
- Gross profit$548.8M96.6%
- Operating costs−$335.2M59.0%
- Operating income$213.6M37.6%
- Interest, other & tax−$28.7M5.1%
- Net income$184.8M32.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed July 28, 2025Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $568.26M$637.18M | −10.8% |
| Cost of Revenue | $19.47M$17.67M | +10.2% |
| Gross Profit | $548.79M$619.51M | −11.4% |
| R&D Expenses | $200.36M$211.15M | −5.1% |
| SG&A Expenses | $134.86M$132.01M | +2.2% |
| Operating Expenses | $354.69M$361.30M | −1.8% |
| Operating Income | $213.58M$275.87M | −22.6% |
| Net Income | $184.85M$226.12M | −18.3% |
| EPS (Basic) | $0.68$0.78 | −12.8% |
| EPS (Diluted) | $0.65$0.77 | −15.6% |
| Shares Outstanding (Basic) | 272.58M289.22M | −5.8% |
| Shares Outstanding (Diluted) | 284.39M293.97M | −3.3% |
05—Questions
Frequently Asked Questions
Why did total revenues decline year over year even though net product revenues grew?
Collaboration revenues fell to $48.2 million in Q2 2025 from $199.6 million in Q2 2024. The prior-year quarter included $150.0 million in license revenue from an Ipsen commercial milestone, which did not recur. Net product revenues rose to $520.0 million from $437.6 million, driven primarily by a 20% increase in CABOMETYX units sold.
How much cash does Exelixis have and how is it being used?
Cash, cash equivalents and marketable securities totaled $1.39 billion at June 30, 2025, compared with $1.75 billion at December 31, 2024. The decrease was primarily due to cash payments to repurchase common stock, along with development, discovery and employee-related spending, partially offset by operating inflows. Management believes existing resources and revenues will support operations for at least 12 months.
What is the status of generic competition for CABOMETYX?
Exelixis settled with Biocon in July 2025, agreeing to a U.S. generic license beginning January 1, 2031, if FDA-approved. Litigation against MSN, Sun and Azurity is ongoing. The filing states it is not possible at this time to determine the likelihood of an unfavorable outcome or estimate potential losses in these matters.
What are the main pipeline catalysts mentioned in the filing?
The company reported positive top-line results from STELLAR-303 in June 2025, showing a statistically significant overall survival improvement versus regorafenib in the ITT population, and plans to discuss a U.S. NDA with regulators. Top-line results from STELLAR-304 are expected in the first half of 2026, depending on event rates. STELLAR-311, a phase 3 trial versus everolimus in NET, was initiated in June 2025.
What share repurchase activity occurred in the quarter?
In the three months ended June 30, 2025, the company repurchased 7,527 thousand shares, with average prices rising from $36.46 in the April period to $42.88 in the period ending July 4, 2025. Cumulatively, under the two $500.0 million programs, Exelixis repurchased 21.7 million shares for $796.3 million.
06—Continue